AACR 2021 | Guadecitabine + atezolizumab in mUC who have progressed after initial checkpoint inhibitor therapy
Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, discusses the rationale and findings of a Phase II trial of guadecitabine, a DNA hypomethylating agent, in combination with atezolizumab in patients with metastatic urothelial carcinoma (mUC) who have progressed following initial checkpoint inhibitor therapy. In this study, a hypomethylating agent was combined with checkpoint blockade with the rationale that the agent may help re-educate the immune system against the tumor as well as prevent T-cell exhaustion, however, the primary endpoint of response was not met. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Disclosures
Elizabeth Plimack, MD, MS, has participated in consultancy work, scientific advisory boards and or data safety monitoring with Aveo, BMS, Calithera, Genentech, Janssen, MEI Pharma, Merck, Pfizer, Seattle Genetics, AstraZeneca and Infinity Pharma; has received honoraria from Clinical Care Options, Creative Educational Concepts, CUA, JADPRO, PER, Research to Practice, Total CME and The Hawaii Society of Clinical Oncology; and has received grants for clinical research from Astellas, BMS, Genentech and Merck.
